←Back to Expert Scholars
Translational Medicine / 转化医学Theranostics, PSMA and DOTATATE
Michael Morris
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Head of Prostate Cancer Section
90
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Michael Morris is a medical oncologist who led the pivotal VISION trial of lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer. His work led to FDA approval of Pluvicto in 2022. His trial leadership has defined the modern PSMA theranostic paradigm.
Share:
🧪Research Fields 研究领域
VISION trial
lutetium-177 PSMA-617
metastatic castration-resistant prostate cancer
theranostics
clinical trial leadership
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Michael Morris 的研究动态
Follow Michael Morris's research updates
留下邮箱，当我们发布与 Michael Morris（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment